Effective detection of BRAF
BRAF
canine
immunohistochemistry
prostate carcinoma
urothelial carcinoma
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
revised:
11
04
2024
received:
20
01
2024
accepted:
12
04
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
25
4
2024
Statut:
aheadofprint
Résumé
Canine urothelial carcinoma (UC) and prostate carcinoma (PC) frequently exhibit the BRAF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Albert Heim Foundation
ID : 148
Informations de copyright
© 2024 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
Knapp DW, Dhawan D, Ramos‐Vara JA, et al. Naturally‐occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans. Front Oncol. 2020;9:1493.
Fulkerson CM, Knapp DW. Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Vet J. 2015;205:217‐225.
de Brot S, Robinson BD, Scase T, et al. The dog as an animal model for bladder and urethral urothelial carcinoma: comparative epidemiology and histology. Oncol Lett. 2018;16:1641‐1649.
de Brot S, Grau‐Roma L, Stirling‐Stainsby C, et al. A Fibromyxoid stromal response is associated with muscle invasion in canine urothelial carcinoma. J Comp Pathol. 2019;169:35‐46.
Grassinger JM, Merz S, Aupperle‐Lellbach H, Erhard H, Klopfleisch R. Correlation of BRAF variant V595E, breed, histological grade and cyclooxygenase‐2 expression in canine transitional cell carcinomas. Vet Sci. 2019;6:31.
Mochizuki H, Breen M. Comparative aspects of BRAF mutations in canine cancers. Vet. Sci. 2015;2:231‐245.
Küchler L, Posthaus C, Jäger K, et al. Artificial intelligence to predict the BRAF V595E mutation in canine urinary bladder urothelial carcinomas. Animals. 2023;13:1‐16.
Mochizuki H, Kennedy K, Shapiro SG, Breen MB. BRAF mutations in canine cancers. PLoS One. 2015;10:1‐9.
Ostrander E, Decker B, Parker HG, et al. Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer—evidence for a relevant model system and urine‐based diagnostic test. Mol Cancer Res. 2012;17:1310‐1314.
Jung H, Bae K, Lee JY, et al. Establishment of canine transitional cell carcinoma cell lines harboring BRAF V595E mutation as a therapeutic target. Int J Mol Sci. 2021;22:9151.
Wong K, Abascal F, Ludwig L, et al. Cross‐species oncogenomics offers insight into human muscle‐invasive bladder cancer. Genome Biol. 2023;24:1‐29.
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279‐3290.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949‐954.
Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res. 2022;28:4618‐4628.
Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42‐50.
Araque KA, Gubbi S, Klubo‐Gwiezdzinska J. Updates on the management of thyroid cancer. Horm Metab Res. 2020;52:562‐577.
Iyer G, al‐Ahmadie H, Schultz N, et al. Prevalence and co‐occurrence of actionable genomic alterations in high‐grade bladder cancer. J Clin Oncol. 2013;31:3133‐3140.
Boulalas I, Zaravinos A, Delakas D, Spandidos DA. Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers. 2009;24:17‐21.
Longo T, McGinley KF, Freedman JA, et al. Targeted exome sequencing of the cancer genome in patients with very high‐risk bladder cancer. Eur Urol. 2016;70:714‐717.
Mochizuki H, Shapiro SG, Breen M. Detection of BRAF mutation in urine DNA as a molecular diagnostic for canine urothelial and prostatic carcinoma. PLoS One. 2015;10:1‐12.
Axiak SM, Oncology D, Bigio A. Canine Prostatic Carcinoma. Compend Contin Educ Vet. 2012;34:E1‐E5.
LeRoy BE, Nadella MVP, Toribio RE, Leav I, Rosol TJ. Canine Prostate Carcinomas Express Markers of Urothelial and Prostatic Differentiation. Vet Pathol. 2004;140:131‐140.
de Brot S, Lothion‐Roy J, Grau‐Roma L, et al. Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component. Vet Comp Oncol. 2022;20:38‐49.
Mendez LD, Wolsefer NS, Asa SL, Wasman J, Yoest JM, Stojanov IJ. The diagnostic utility of BRAF VE1 mutation‐specific immunohistochemistry in ameloblastoma. Mod Pathol. 2022;35:1570‐1577.
Cheng LY, Haydu LE, Song P, et al. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021;11:9043.
Singarayer R, Mete O, Perrier L, et al. A systematic review and meta‐analysis of the diagnostic performance of BRAF V600E immunohistochemistry in thyroid histopathology. Endocr Pathol. 2019;30:201‐218.
Rasteiro AM, Sá E Lemos E, Oliveira PA, Gil da Costa RM. Molecular markers in urinary bladder cancer: applications for diagnosis, prognosis and therapy. Vet Sci. 2022;9:107.
Gentilini F, Palgrave CJ, Neta M, et al. Validation of a Liquid Biopsy Protocol for Canine BRAFV595E Variant Detection in Dog Urine and its Evaluation as a Diagnostic Test Complementary to Cytology. Front Vet Sci. 2022;9:1‐11.
Aupperle‐Lellbach H, Grassinger J, Hohloch C, Kehl A, Pantke P. Diagnostische Aussagekraft der BRAF‐Mutation V595E in Urinproben, Ausstrichen und Bioptaten beim kaninen Übergangszellkarzinom. Tierärztliche Prax Ausgabe K Kleintiere/Heimtiere. 2018;46:289‐295.
Ito T, Tanaka Y, Murata M, Kaku‐Ito Y, Furue K, Furue M. BRAF Heterogeneity in Melanoma. Curr Treat Options Oncol. 2021;22:20.
Meuten DJ, Meuten TLK. Tumors of the Urinary System in Tumors in Domestic Animals. 5th ed. John Wiley & Sons Inc; 2017.
Palmieri C, Foster RA, Grieco V, et al. ScienceDirect histopathological terminology standards for the reporting of prostatic epithelial lesions in dogs. J Comp Pathol. 2019;171:30‐37.
Schirosi L, Strippoli S, Gaudio F, et al. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients ? BMC Cancer. 2016;16:905.
Dolezal JM, Trzcinska A, Liao CY, et al. Deep learning prediction of BRAF‐RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary‐like nuclear features. Mod Pathol. 2021;34:862‐874.
Broekaert SMC, Roy R, Okamoto I, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 2010;23:763‐770.
Yamasaki H, Uematsu Y, Okano K, et al. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs. In Vitro Cell Dev Biol Anim. 2022;15:898‐911.
Sakai K, Maeda S, Saeki K, et al. ErbB2 Copy Number Aberration in Canine Urothelial Carcinoma Detected by a Digital Polymerase Chain Reaction Assay. Vet Pathol. 2020;57:56‐65.
Maeda S, Yoshitake R, Chambers JK, et al. BRAF mutation associates CCL17 expression and regulatory T cell recruitment in urothelial carcinoma of dogs. Vet Pathol. 2021;58:971‐980.
Ny L, Hernberg M, Nyakas M, et al. BRAF mutational status as a prognostic marker for survival in malignant melanoma : a systematic review and meta‐analysis. Acta Oncol. 2020;59:833‐844.
Atkins MB, Lee SJ, Chmielowski B, et al. Combination Dabrafenib and Trametinib versus combination Nivolumab and Ipilimumab for patients with advanced BRAF ‐mutant melanoma: the DREAMseq trial ‐ ECOG‐ACRIN EA6134. J Clin Oncol. 2023;41:186‐197.
Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus Trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023;389:1108‐1120.
Rossman P, Zabka TS, Ruple A, et al. Phase I/II trial of vemurafenib in dogs with naturally occurring, BRAF‐mutated urothelial carcinoma. Mol Cancer Ther. 2021;20:2177‐2188.
Li Q, Chen K, Zhang T, et al. Understanding sorafenib‐induced ferroptosis and resistance mechanisms: implications for cancer therapy. Eur J Pharmacol. 2023;955:175913.
Cronise KE, Hernandez BG, Gustafson DL, Duval DL. Identifying the ErbB / MAPK signaling Cascade as a therapeutic target in canine bladder cancer. Mol Pharmacol. 2019;96:36‐46.
Yancovitz M, Litterman A, Yoon J, et al. Intra‐ and inter‐tumor heterogeneity of BRAF V600Emutations in primary and metastatic melanoma. PLoS One. 2012;7:1‐8.
Wilmott JS, Menzies AM, Haydu LE, et al. BRAF V600E protein expression and outcome from BRAF inhibitor treatment in BRAF V600E metastatic melanoma. Br J Cancer. 2013;108:924‐931.
Manfredi L, Meyer N, Tournier E, et al. Highly concordant results between immunohistochemistry and molecular testing of mutated V600E BRAF in primary and metastatic melanoma. Acta Derm Venereol. 2016;96:630‐634.
Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399‐5404.
Sholl LM. A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications. Precis Cancer Med. 2020;3:26.
Grassinger J, Gmbh L, Kg C. Nachweis der BRAF‐mutation bei kaninen Prostataerkrankungen detection of BRAF mutation in canine prostatic diseases Einleitung. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2019;47:313‐320.